Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5501 CAR-NK cell therapy in systemic lupus erythematosus
NCT07358988Phase 1Not yet recruiting
- Sponsor
- Rui Therapeutics
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5501 in systemic lupus erythematosus (SLE), sponsored by Rui Therapeutics. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Adverse Events at 52 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
KN5501
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07358988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358988.